Management of Patients With Brain-onset Oligometastatic Non-small-cell Lung Cancer (NSCLC)
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 46
- 试验地点
- 1
- 主要终点
- Progression free survival (PFS)
研究概览
简要总结
75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized. The question is therefore which therapeutic strategy is optimal in such disease presentation. We will analyze the impact of different therapeutic strategies on patients treated at Bordeaux University Hospital and the Bergonié Institute
详细描述
75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized. The question is therefore which therapeutic strategy is optimal in terms of disease control: local treatment of the main tumor and brain versus systemic treatment with chemotherapy and immunotherapy. We will analyze the impact of these 2 strategies on patients treated at Bordeaux University Hospital and the Bergonié Institute.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Consecutive patients managed at Bordeaux University Hospital
- •Non-small-cell lung cancer
- •Oligometastatic brain cancer (fewer than 5 lesions at diagnosis)
- •Patient over 18 years old
排除标准
- •Oncogenic addiction EGFR, ALK, ROS1
- •Patient with concomitant cancer
- •Patient with prior treatment for lung cancer in the year preceding diagnosis at metastatic stage
研究组 & 干预措施
Local treatments
Local multimodal treatments (thoracic surgery/radiotherapy + brain surgery/radiotherapy)
干预措施: Standard treatments / multiple strategies (Other)
Systemic treatment
Chemoimmunotherapy combination
干预措施: Standard treatments / multiple strategies (Other)
结局指标
主要结局
Progression free survival (PFS)
时间窗: Once, at progression or death from any cause
Time from random assignment in a clinical trial to disease progression or death from any cause
次要结局
- PFS from the date of the next treatment to disease progression or death from any cause (PFS2)(Once, at progression or death from any cause)
- Overall survival (OS)(Once, death from any cause or lost of follow-up)